Alaunos Therapeutics (TCRT) FCF Margin (2011 - 2025)
Alaunos Therapeutics (TCRT) reported FCF Margin of 18433.33% for Q4 2025, down 363333.0% on a YoY basis from N/an in Q4 2024, and up 52.25% quarter-over-quarter from 38600.0% in Q1 2025.
Alaunos Therapeutics (TCRT) FCF Margin (2011 - 2025) Analysis & Trends
Alaunos Therapeutics has reported FCF Margin for 13 years, with the latest figure at 18433.33% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin fell 363333.0% year-over-year to 18433.33%; the trailing twelve-month figure through Mar 2026 stood at 104300.0% (down 6604000.0% YoY), and the FY2025 full-year result was 59340.0%, down 963000.0% from the prior year.
- FCF Margin for Q4 2025 stood at 18433.33%, up from 38600.0% in the prior quarter.
- The five-year high for FCF Margin was 211.58% in Q3 2022, with the low at 774250.0% in Q4 2021.
- Historically, FCF Margin has averaged 187756.08% across 5 years, with a median of 42025.0% in 2024.
- Annual changes were most pronounced in 2023 — FCF Margin plunged 67262727 bps — and 2024, when it jumped 72370000 bps.
- Alaunos Therapeutics' FCF Margin stood at 774250.0% in 2021, then soared by 91 bps to 65872.73% in 2022, then tumbled by 1021 bps to 738500.0% in 2023, then surged by 98 bps to 14800.0% in 2024, then dropped by 25 bps to 18433.33% in 2025.
- The last three FCF Margin figures came in at 18433.33% (Q4 2025), 38600.0% (Q1 2025), and 14800.0% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.31 Mn | 3.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18,433.33% |
| Mar 31, 2025 | -38,600.00% |
| Dec 31, 2024 | -14,800.00% |
| Jun 30, 2024 | -42,025.00% |
| Mar 31, 2024 | -191,700.00% |
| Dec 31, 2023 | -738,500.00% |
| Jun 30, 2023 | -178,425.00% |
| Dec 31, 2022 | -65,872.73% |
| Sep 30, 2022 | -211.58% |
| Dec 31, 2021 | -774,250.00% |
| Sep 30, 2021 | -2,499.25% |
| Mar 31, 2018 | -13,086.99% |
| Dec 31, 2017 | -778.46% |
| Sep 30, 2017 | -800.31% |
| Jun 30, 2017 | -973.70% |
| Mar 31, 2017 | -916.41% |
| Dec 31, 2016 | -823.17% |
| Sep 30, 2016 | -896.18% |
| Jun 30, 2016 | -894.11% |
| Mar 31, 2016 | -824.58% |